
Cornelia Schuster

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8457408/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension. PLoS ONE, 2012, 7, e38364.	2.5	46
2	ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. Scientific Reports, 2019, 9, 17471.	3.3	26
3	Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma. PLoS ONE, 2019, 14, e0210399.	2.5	20
4	Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study. PLoS ONE, 2016, 11, e0155242.	2.5	15
5	Ipilimumab in a realâ€world population: A prospective Phase <scp>IV</scp> trial with longâ€term followâ€up. International Journal of Cancer, 2022, 150, 100-111.	5.1	11
6	Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy. Journal of Pathology: Clinical Research, 2019, 5, 53-62.	3.0	7
7	A randomized phase Ib/II study of the selective small molecule axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma Journal of Clinical Oncology, 2018, 36, 9548-9548.	1.6	3
8	Abstract 3704: Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension in a single-arm Phase II study. , 2012, , .		0
9	Abstract 2828: High expression of heat shock protein 27 in metastases is correlated with response to bevacizumab monotherapy in patients with metastatic melanoma. , 2014, , .		0
10	The Tumor Microenvironment in Cutaneous Melanoma: Friend or Foe. , 2017, , 481-506.		0
11	Abstract CT056: A Phase Ib/II randomised open label study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib compared to pembrolizumab or dabrafenib/trametinib alone, in patients with advanced non-resectable (Stage IIIc) or metastatic (Stage IV) melanoma. , 2017, , .		0